BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 4, 2010
View Archived Issues
After Trauma, Mitochondrial DNA Set Off Sepsis-Like Response
Read More
Ataluren's DMD Expedition Hits Bump with Failed Phase IIb Trial
Read More
NiCox, Bausch & Lomb Ink $179.5M Deal in Glaucoma
Read More
Clinic Roundup
Read More
Stock Movers for March 4, 2010
Read More
Other News To Note
Read More
Financings Roundup
Read More
Medivation Rocked by Dimebon Miss in Late-Stage AD Study
Shares in Medivation Inc. fell 67.5 percent Wednesday on news that its Phase III trials of Alzheimer's drug candidate Dimebon missed all of the study's stated goals, smashing some high hopes on Wall Street. (BioWorld Today)
Read More
ExonHit Emerges a Winner in Allergan, BMS Pain Deal
Read More